Diabetic Patients all across Mumbai sign a Petition against Glucostrip Price

by Rishika Gupta on  December 14, 2017 at 11:46 AM Diabetes News
RSS Email Print This Page Comment bookmark
Font : A-A+

Diabetic patients all across Mumbai have signed a price reduction petition against the glucostrips, the count of signatures have risen to 15,000 in just over a month. The whole petition was signed to highlight the growing inflation in essential medical products.
Diabetic Patients all across Mumbai sign a Petition against Glucostrip Price
Diabetic Patients all across Mumbai sign a Petition against Glucostrip Price

The petition that was signed at the city's Gadge Diabetes Center hopes to make the government realize that a reduction of the glucostrip price would make it affordable for all.

Show Full Article


According to the organizers of the initiative, the petition will be submitted to the price control body National Pharmaceutical Pricing Authority and the Union Health Ministry.

"The cost of health care is drastically increasing. The manufacturing cost of a glucostrip is 50 paise but the patient is charged Rs 25 to Rs 30. Those who need to keep a check on their blood glucose levels more than once a day will have to shell more than Rs 150 which may not be feasible for all," said Pradeep Gadge, a Mumbai-based diabetologist.

According to him, the petition was signed by over 15,000 patients in just over a month.

"If one keeps in mind the prevalence of diabetes in the country, the need of the hour is price ceiling of glucostrips. This will help make it affordable for all," said Gadge.

According to the World Health Organization (WHO), in 2008, an estimated 347 million people in the world suffered from diabetes and the prevalence is growing, particularly in low and middle income countries.

India had 69.2 million people living with diabetes (8.7 percent), as per the 2015 data. Of these, it remained undiagnosed in more than 36 million people.



Source: IANS

Post a Comment

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
Notify me when reply is posted
I agree to the terms and conditions

Recommended Reading

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Premium Membership Benefits

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Stay Connected

  • Available on the Android Market
  • Available on the App Store

News Category

News Archive